4
Changes in Ownership
RHYTHM PHARMACEUTICALS, INC. Filed Acc 0001649904-26-000013
Chief Scientific Officer sold 7,763 shares at an average $117.57 ($912,703)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Garfield Alastair Chief Scientific Officer | 2026-08-13 | Sale 10b5-1 | −2,007 | $116.11 | $233,031 | 8,051 | D: show line 1 in the form |
| Garfield Alastair Chief Scientific Officer | 2026-08-13 | Sale 10b5-1 | −1,556 | $117.08 | $182,170 | 6,495 | D: show line 2 in the form |
| Garfield Alastair Chief Scientific Officer | 2026-08-13 | Sale 10b5-1 | −3,400 | $118.28 | $402,167 | 3,095 | D: show line 3 in the form |
| Garfield Alastair Chief Scientific Officer | 2026-08-13 | Sale 10b5-1 | −800 | $119.17 | $95,335 | 2,295 | D: show line 4 in the form |
| Open-market sales · 7,763 sh · avg $117.57 · $912,703 | |||||||
Loading xslF345X06/form4.xml…